Our company believes that no one should go without the medicines or vaccines they need.

That is why our company provides our medicines and adult vaccines for free to people who do not have prescription drug or health insurance coverage and who, without our assistance, could not afford these medicines and vaccines. This is consistent with our company’s long-held values and tradition of putting patients first.

More than 55 years ago, our company created our first U.S. patient assistance program (PAP) to keep affordable medicines within patients’ reach. Today, our patient assistance offerings include several programs. Through these programs, we have provided more than 34 million free prescriptions and vaccines, representing a total value (wholesale acquisition cost) of more than $3.6 billion in the past 12 years alone.


For details on all of our U.S. patient assistance programs, including eligibility requirements, visit or call 1-800-PAP-5400 (1-800-727-5400).

Communicating Our Programs to Doctors & Consumers

We are working to raise awareness of our patient assistance programs among doctors and eligible patients via brochures and applications distributed by our sales representatives to physicians’ offices and clinics nationwide. All toll-free phone lines for our medicines include an option for patients to learn about our patient assistance programs. In addition, information about these programs is being added to all of our new direct-to-consumer advertisements, including a phone number for more information.

Partnership for Prescription Assistance

We also participate in the pharmaceutical industry initiative Partnership for Prescription Assistance (PPA). The Partnership brings together America’s pharmaceutical companies, as well as doctors, patient advocacy organizations and civic groups, to help low-income, uninsured patients get free or nearly free brand-name medicines. PPA does this through a single website that provides information for and access to more than 475 public and private patient-assistance programs, including more than 200 programs offered by pharmaceutical companies like ours. To date, PPA has helped millions of Americans get free or reduced-cost prescription medicines.

Our participation in PPA underscores the company’s commitment to helping the uninsured gain access to our medicines. To learn more about the Partnership for Prescription Assistance, visit


You do not have to be a U.S. citizen. If you do not meet the prescription drug coverage criteria, but your income meets the program criteria and there are special circumstances of financial and medical hardship that apply to your situation, you can request that an exception be made for you.
For income limits in Alaska, Hawaii, Puerto Rico, the U.S. Virgin Islands and Guam, please call 1-800-727-5400.
* Offered through Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A.
** Offered through the Merck Patient Assistance Program, Inc.

Patient Assistance Programs Performance20102011201220132014
Patients utilizing our company's Patient Assistance Programs1343,382379,500444,178400,000301,713
30-day prescriptions filled under our company's Patient Assistance Programs (millions)
Total value of our company's medicines dispensed under our Patient Assistance Programs (US$M)3322.8301.2559.0566.4432.9
1 Totals represent 2011 to 2014 volumes of the U.S. Merck Patient Assistance Program, the U.S. Merck Vaccine Assistance Program, the U.S. Merck Patient Bulk Replacement Patient Assistance Program, the SUPPORT Program, the ACT Program and the U.S. Merck Hotline. Totals for 2009 and 2010 include the U.S. Merck Patient Assistance Program, the U.S. Merck Vaccine Patient Assistance Program, the Schering-Plough Patient Assistance Program and the U.S. Merck/Schering-Plough Pharmaceutical Patient Assistance Program.
2 Totals are based on the U.S. wholesale acquisition cost (WAC) and cover all programs.

The main driver of the decrease in patient and prescription volumes for 2013–2014 is the periodic changes in the products covered by the various patient assistance programs. These changes are due, in part, to company divestitures, the introduction of competing products and the availability of generic alternatives.

 Public Policy   |   Site Map   |   Contact Us   |   FAQ   |   Privacy   |   Terms of Use

Copyright © 2009-2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A. All rights reserved.

TRUSTe European Safe Harbor certification   Validate TRUSTe privacy certification